Transobturator tape versus retropubic tension-free vaginal tape for stress urinary incontinence: 5-year safety and effectiveness outcomes following a randomised trial.

Introduction And Hypothesis: In a randomised trial comparing transobturator tape (TOT) to retropubic tension-free vaginal tape (TVT) for women with stress urinary incontinence (SUI), vaginal examination at 12 months showed that tapes were palpable for 80.0 % of the TOT group versus 26.7 % of the TVT group.

Single incision device (TVT Secur) versus retropubic tension-free vaginal tape device (TVT) for the management of stress urinary incontinence in women: a randomized clinical trial.

Background: In 2006, Ethicon Inc. introduced a new minimally invasive single incision sling device for the surgical treatment of stress urinary incontinence, the Gynecare TVT Secur®. For device licensing, no new evidence of TVT Secur efficacy and safety was needed: rather evidence was provided of the long-term follow-up of patients who had a procedure using a predecate retropubic tension-free vaginal tape device.

Transobturator tape compared with tension-free vaginal tape for stress incontinence: a randomized controlled trial.

Objective: To compare the effectiveness of transobturator tape with tension-free vaginal tape (TVT) in terms of objective cure of stress urinary incontinence (SUI) at 12 months postoperatively.

Method: Women with SUI were randomly allocated to either transobturator tape or TVT procedures and reviewed at 12 months after surgery. The primary outcome was objective evidence of "cure," evaluated by standardized pad test (cure defined as less than 1 g urine leaked).

Sensitivity of human lymphocytes to genotoxic effect of n-methyl-n-nitrosourea: possible relation to gynecological cancers.

Unlabelled: The aim of this work is to study responses of PHA-stimulated and resting lymphocytes to methylating agent N-methyl-N-nitrosourea (MNU) and to compare sensitivity to this agent of healthy donor lymphocytes and lymphocytes from patients with gynecological cancers.

Methods: Cytotoxicity of MNU, apoptotic death of lymphocytes, was evaluated using two common tests--annexin V-FITC detection assay and live/dead double staining assay (nuclear morphological changes). Genotoxic effect of the agent was determined as delayed (secondary) DNA double strand breaks (DSBs) using neutral comet assay both conventional variant and modified for detection of bromodeoxyuridine-labelled comets, produced by proliferating lymphocytes only.

[The use of 1H-NMR spectroscopy for the prognosis of overall survival of breast cancer patients].

The pool of low-molecular metabolites in untreated breast cancer patients was investigated by high-resolution 1H-NMR spectrometry. It was found that the delta = 1.75 m.

[Comparative study of cytosolic proteins in normal and neoplastic ovaries by polyacrylamide electrophoresis].

The report discusses the data on cytoplasmic protein occurrence in ovarian tissue (106) obtained by polyacrylamide gel electrophoresis. They were identified in normal ovarian tissue (15), benign tumor (16), primary malignant tumor (55) and tumor tissue after chemotherapy (20). A band was detected in the area of molecular 36 cD in malignant epithelial tumor tissue which was not seen in either normal, benign tumor tissue or after successful chemotherapy.

The use of 1H-NMR spectroscopy for predicting the efficiency of neoadjuvant chemotherapy of breast cancer.

The pool of low-molecular-weight metabolites was studied in patients with breast cancer by high-resolution 1H-NMR spectroscopy. In order to predict the efficiency of treatment, mathematical regression analysis was carried out with consideration for some clinical morphological characteristics of patients, chemotherapy protocols, and the degree of therapeutic pathomorphosis. The efficiency of drug therapy was largely determined by metabolic status of tumors in untreated patients with breast cancer.

[The new antitumor drug cycloplatam: cytotoxicity and DNA interstrand cross-linking].

Cytotoxicity genetic mechanisms such as induction of SOS-repair, excision repair and interstrand coupling induced by cycloplatam or ammine (cyclopentyl amine)-S(-) malatoplatinum (II), a new antitumor drug, were for the first time studied in comparison to those of the known drug cis-diammine dichloroplatinum (II) (DDP) in a model system of Escherichia coli. In the cells of E. coli the cycloplatam cytotoxicity was much lower than that of DDP.

[Modulation of the antitumor activity of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosoure a by O(6)-methyl-2'-deoxyguanosine--a new inhibitor of O(6)-alkylguanine-DNA-alkyltransferase].

O6-Methyl-2'-deoxyguanosine (O6-MedG), a novel inhibitor of O6-alkylguanine-DNA alkyltransferase (O6-AGT), has been synthesized. The ability of O6-MedG to deplete the O6-AGT activity in leukemia L1210 and melanoma B16 cells in vivo has been studied. After intraperitoneal administration of O6-MedG to mice bearing leukemia L1210 or melanoma B16, the activity of O6-AGT in tumour cells decreased by 50%.

[Biochemical mechanisms of resistance to a new antineoplastic agent amin(cyclopeptidylamin)-S-(-)-malatoplatinum (II) (cycloplatam)].

The "in vivo" effect of cycloplatam on DNA synthesis in leukemia P388/o (parent strain), P388/c (cycloplatam-resistant strain) and in some organs of tumour-bearing mice, such as spleen, kidney, gastrointestinal mucosa (GI mucosa) and bone marrow, has been studied. Cycloplatam induced a deep and stable inhibition of DNA synthesis in leukemia cells and kidney. DNA synthesis in normal dividing cells (GI mucosa, bone marrow, spleen) was shown to recover more rapidly than in leukemia cells and kidney after cycloplatam treatment.

[Changes in the replication apparatus and phosphorus-containing metabolite pool in experimental tumors in animals during development].

Activity of replicase complex enzymes involving thymidine kinase (TK), ribonucleotide reductase (RR), DNA-polymerases alpha and beta as well as DNA synthesis and single breaks in DNA were studied during growth of P388 ascites tumor. Under these conditions the rate of DNA synthesis was distinctly decreased via salvage pathway and de novo. Single breaks were not detected in the preexistent DNA within various periods after transplantation of P338 leukemic cells.

[Effects of daunorubicin and its nitroxyl analog on the synthesis of nucleic acids].

The impact of daunorubicin, emoksil in sublethal doses and daunorubicin mixtures with a nitroxyl radical of 2,2,6,6-tetramethyl-4-oxopiperidine-1-oxyl (NR) on synthesis of DNA and RNA in some organs of rats was studied. Daunorubicin and emoksil induced marked (by 80 to 90%) inhibition of DNA synthesis in all the examined organs even within the first hours of administration. In the heart, DNA synthesis remained lower by the end of the experiment.

[Effect of rubomycin and its paramagnetic analog on DNA synthesis].

Ruboxyl, a paramagnetic analog of rubomycin, was synthesized and subjected to a preliminary investigation at the Institute of Chemical Physics of the Academy of Sciences of the USSR. The drug is characterized by a higher antitumor activity, broader spectrum and lower general and cardiac toxicity. This is the first attempt of comparative biochemical investigation of rubomycin, ruboxyl and the nitroxyl radical at the level of DNA replication.